3-(1-dimethylaminoethyl)phenol
a rivastigmine metabolite; structure in first source
Also Known As:
NAP 226-90; NAP-226-90; NAP226-90
Networked: 4
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Chen, Su-Hwei:
2 articles
(01/2012 - 02/2009)
|
| 2. | Yang, Yuan-Han:
2 articles
(01/2012 - 02/2009)
|
| 3. | Callegari, Francesca:
1 article
(10/2016)
|
| 4. | Gsteiger, Sandro:
1 article
(10/2016)
|
| 5. | Lefèvre, Gilbert:
1 article
(10/2016)
|
| 6. | Xiong, Yuan:
1 article
(10/2016)
|
| 7. | Srinivas, Nuggehally R:
1 article
(07/2016)
|
| 8. | Chen, Chun-Hung:
1 article
(01/2012)
|
| 9. | Chou, Mei-Chuan:
1 article
(01/2012)
|
| 10. | Liu, Ching-Kuan:
1 article
(01/2012)
|
Related Diseases
| 1. | Alzheimer Disease (Alzheimer's Disease)
07/01/2016
- " Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples." 01/01/2012
- " The aim of this small pilot study was to evaluate the association between plasma concentrations of rivastigmine and its metabolite, NAP 226-90, and cognitive function in patients with Alzheimer's disease (AD). " 01/01/2012
- " Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients." 10/01/2016
- " We describe here a population pharmacokinetic analysis of the possible effects of renal impairment on steady-state plasma concentrations of rivastigmine and its metabolite NAP226-90 after rivastigmine patch (5 cm2 [4.6 mg/24 h], 10 cm2 [9.5 mg/24 h], 15 cm2 [13.3 mg/24 h], and 20 cm2 [17.4 mg/24 h]) and capsule (1.5, 3, 4.5, and 6 mg/12 h) treatment in patients with Alzheimer's disease. " 02/01/2009
- " Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease."
|
|
Related Drugs and Biologics
Related Therapies and Procedures